bioAffinity Technologies, Inc. has taken significant steps to amend its corporate structure by reducing the number of authorized shares of common stock. This decision was made during a special meeting of stockholders held on November 20, 2026, and is aimed at streamlining the company’s operations and enhancing shareholder value.

The company’s stockholders approved an amendment to its Certificate of Incorporation, decreasing the total number of authorized shares from 350 million to 200 million. This charter amendment became effective immediately upon filing with the Secretary of State of Delaware.

Background

bioAffinity Technologies, Inc., operating under the SIC code 8731, specializes in services related to commercial physical and biological research. The company is publicly traded on the Nasdaq under the ticker symbols BIAF and BIAFW. Its recent filings include an 8-K on November 20, 2026, detailing the amendments made to its corporate structure.

What the Filing Says

The filing states, "stockholders approved an amendment to the Company’s Certificate of Incorporation to decrease the total number of authorized shares of common stock from 350,000,000 shares to 200,000,000 shares." This change reflects the company’s strategic focus on optimizing its capital structure.

Impact

This amendment may positively affect current shareholders by potentially increasing the value of their holdings through a more efficient share structure. The reduction in authorized shares may also signal to investors that the company is taking proactive measures to manage its equity more effectively. This is particularly relevant in the context of the competitive landscape in the commercial physical and biological research sector.

What's Next

The filing does not specify what happens next, but the company may focus on leveraging this new share structure to enhance its operational strategies and investor relations moving forward.

For more details, refer to the filing with accession number 0001493152-26-053534.